Guardant Health, Inc.
For the period ended Dec 31, 2025. Filed Feb 19, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 19, 2026
GH$158.79+5.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
(in thousands, except per share data)
| Year Ended December 31, | |||
|---|---|---|---|
| 2025 | 2024 | 2023 | |
| Revenue | $982,021 | $739,016 | $563,948 |
| Costs and operating expenses: | |||
| Cost of revenue | 349,007 | 289,799 | 227,052 |
| Research and development expense | 364,191 | 347,753 | 367,194 |
| Sales and marketing expense | 494,661 | 364,935 | 295,227 |
| General and administrative expense | 211,410 | 180,123 | 155,800 |
| Other operating expense | — | — | 83,400 |
| Total costs and operating expenses | 1,419,269 | 1,182,610 | 1,128,673 |
| Loss from operations | (437,248) | (443,594) | (564,725) |
| Interest income | 34,095 | 53,691 | 35,365 |
| Interest expense | (3,897) | (2,581) | (2,578) |
| Other income (expense), net | (10,490) | (42,605) | 53,174 |
| Loss before (benefit from) provision for income taxes | (417,540) | (435,089) | (478,764) |
| (Benefit from) provision for income taxes | (1,263) | 1,284 | 685 |
| Net loss | $(416,277) | $(436,373) | $(479,449) |
| Net loss per share, basic and diluted | $(3.32) | $(3.56) | $(4.28) |
| Weighted-average shares used in computing net loss per share, basic and diluted | 125,374 | 122,745 | 111,988 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.